A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide
Obesity Reviews · 2026-06 · 27 (6)
DOI: 10.1111/obr.70077 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Obesity Reviews, online erschienen am 05.01.2026. Verfasst von Anna K Jansson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Food and Nutrition Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. Hauptthemen laut MEDLINE: Liraglutide, Glucagon-Like Peptides, Tirzepatide, Hypoglycemic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Introduction
With the growing use of GLP‐1/GIP receptor agonist medications, their impact on dietary intake and quality remains unclear. This systematic review examined how randomized controlled trials (RCT) prescribing liraglutide, semaglutide, or tirzepatide assessed and reported dietary intake and quality as outcome measures, alongside weight loss and/or glycemic control, and identified gaps in the use and methodological quality of dietary assessment methods.
Methods
Medline, Embase, Cochrane, Scopus, and CINAHL were systematically searched between January 2008–January 2025 (adults) and January 2014–January 2025 (children/adolescents). The review was registered with the Open Science Framework (DOI: 10.17605/OSF.IO/XPNGY ).
Results
Forty‐three articles from 41 unique RCTs, comprising 50,690 participants ( n = 688 children/adolescents, n = 50,002 adults) were included. Except for two studies targeting adults (one published and one unpublished data from an included study), this review found no other studies that assessed or reported dietary intake or changes in diet. Both reported a reduction in the total energy intake and altered macronutrient distribution in the medication plus diet group, although one was not significantly different from medication alone. Quality of assessment methods used was categorized as “poor” and “acceptable,” respectively. These results highlight a critical gap in the literature.
Conclusion
Only 2/41 studies (≈5%) reported or assessed dietary intake or evaluated diet changes secondary to GLP‐1/GIP RA medication use. This review highlights a major gap in the evidence requiring urgent attention. More high‐quality research, using validated dietary assessment methods as outcome measures in RCTs is needed to understand how these medications impact diet and diet quality, nutrient intake, and chronic disease risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Food and Nutrition Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
- School of Health Sciences, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
- Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden.
- Allied Health Professionals, Karolinska University Hospital, Stockholm, Sweden.
- Department of Health Professions, Division of Nutrition and Dietetics, Bern University of Applied Sciences, Bern, Switzerland.
- School of Environmental & Life Sciences, College of Engineering, Science & Environment, University of Newcastle, Ourimbah, New South Wales, Australia.
ORCID-Profile: Anna K Jansson, Linnea Hedin, Erin D Clarke, Jordan Stanford, Rachael M Taylor, Marie Löf, Clare E Collins
Förderung
- National Health and Medical Research Council
Zitieren
APA
Jansson, A. K., Gómez-Martín, M., Hedin, L., Clarke, E. D., Cross, V., Stanford, J., Taylor, R. M., Bogl, L. H., De Vlieger, N., Koochek, A., Löf, M., Asher, R. C., Burrows, T., Bucher, T., Sullivan, C., Nowicka, P., & Collins, C. E. (2026). A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide. Obesity Reviews, 27(6). https://doi.org/10.1111/obr.70077
Vancouver
Jansson AK, Gómez-Martín M, Hedin L, Clarke ED, Cross V, Stanford J, et al. A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide. Obesity Reviews. 2026;27(6). doi:10.1111/obr.70077
BibTeX
@article{Jansson2026,
author = {Jansson, Anna K and Gómez-Martín, María and Hedin, Linnea and Clarke, Erin D and Cross, Victoria and Stanford, Jordan and Taylor, Rachael M and Bogl, Leonie H and De Vlieger, Nienke and Koochek, Afsaneh and Löf, Marie and Asher, Roberta C and Burrows, Tracy and Bucher, Tamara and Sullivan, Clair and Nowicka, Paulina and Collins, Clare E},
title = {A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide},
journal = {Obesity Reviews},
year = {2026},
volume = {27},
number = {6},
doi = {10.1111/obr.70077}
}
EUVIMED